These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12142644)

  • 1. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer.
    Hilleret H; Voirol P; Bovier P; Giannakopoulos P; Zullino D; Baumann P; Giroud C; Rivier L; Eap CB
    Ther Drug Monit; 2002 Aug; 24(4):567-9. PubMed ID: 12142644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
    Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
    J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of desipramine toxicity with citalopram.
    Ashton AK
    J Clin Psychiatry; 2000 Feb; 61(2):144. PubMed ID: 10732663
    [No Abstract]   [Full Text] [Related]  

  • 5. [Toxicologic findings in suicide with doxepin and paroxetine].
    Musshoff F; Grellner W; Madea B
    Arch Kriminol; 1999; 204(1-2):28-32. PubMed ID: 10489589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of clorazepate in pregnant and non-pregnant women.
    Rey E; d'Athis P; Giraux P; de Lauture D; Turquais JM; Chavinie J; Olive G
    Eur J Clin Pharmacol; 1979 Apr; 15(3):175-80. PubMed ID: 37089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine not to blame.
    Altman CA
    J Anal Toxicol; 1999; 23(4):297-8. PubMed ID: 10445495
    [No Abstract]   [Full Text] [Related]  

  • 9. Case report: Therapeutic drug monitoring and CYP2D6 phenoconversion in a protracted paroxetine intoxication.
    Damborská A; Hanáková L; Pindurová E; Horská K
    Front Pharmacol; 2024; 15():1444857. PubMed ID: 39295933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of paroxetine in three postmortem cases.
    Vermeulen T
    J Anal Toxicol; 1998 Oct; 22(6):541-4. PubMed ID: 9788532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.
    Güzey C; Norström A; Spigset O
    Ther Drug Monit; 2002 Jun; 24(3):436-7. PubMed ID: 12021638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyponatremia following acute overdose with paroxetine.
    Johnsen CR; Hoejlyng N
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):333-5. PubMed ID: 9660041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antacids on absorption of clorazepate.
    Chun AH; Carrigan PJ; Hoffman DJ; Kershner RP; Stuart JD
    Clin Pharmacol Ther; 1977 Sep; 22(3):329-35. PubMed ID: 19188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.
    Ozdemir V; Tyndale RF; Reed K; Herrmann N; Sellers EM; Kalow W; Naranjo CA
    J Clin Psychopharmacol; 1999 Oct; 19(5):472-5. PubMed ID: 10505591
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients.
    Leucht S; Hackl HJ; Steimer W; Angersbach D; Zimmer R
    Psychopharmacology (Berl); 2000 Jan; 147(4):378-83. PubMed ID: 10672631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
    Bloomer JC; Woods FR; Haddock RE; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1992 May; 33(5):521-3. PubMed ID: 1388041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
    Venkatakrishnan K; Obach RS
    Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.
    Findling RL; Nucci G; Piergies AA; Gomeni R; Bartolic EI; Fong R; Carpenter DJ; Leeder JS; Gaedigk A; Danoff TM
    Neuropsychopharmacology; 2006 Jun; 31(6):1274-85. PubMed ID: 16319918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.